Opella, the consumer healthcare company that Sanofi spun out in 2025, has launched Telfast Kids in the United Arab Emirates. It did not open with a billboard. It opened with a room full of clinicians. According to Dawaa News, the launch ran as a two-day scientific programme with the Emirates Pediatric & Neonatal Society (EPNS) and brought together about 200 doctors and pharmacists to discuss allergy care for children and their families.
That choice of launch format is the story. Telfast is a fexofenadine antihistamine brand, and children's allergy is a category where the parent buys, the pharmacist often advises, and the paediatrician sets the tone. A company that wants to win a paediatric over-the-counter (OTC) category in the UAE has to earn trust with all three. Opella appears to have started with the two professional groups first.
For consumer health, OTC and pharma teams across the UAE and the wider GCC, the launch is a useful case study in how paediatric self-care products are introduced in the region, and in the evidence a team needs before, during and after such a launch.
A note on sources. The launch details come from the Dawaa News MENA report of 3 November 2026, which itself cites a LinkedIn post by Hossam Abo Ouf, Opella's Country Head for Saudi Arabia and the UAE. Opella's corporate facts come from the Sanofi press release of 30 April 2025 and an Opella press release carried by Zawya on 1 July 2026. Allergy prevalence figures come from peer-reviewed studies indexed in PubMed. Regulatory context comes from the UAE Ministry of Health and Prevention (MoHAP) and the Emirates News Agency (WAM). Where the public record is silent, we say so rather than fill the gap.
How Dawaa News surfaced the story
Dawaa News posted the item on its LinkedIn company page (short link lnkd.in/ezFdkvQp) under the Arabic headline "أوبيلا تطلق Telfast Kids لعلاج الحساسية لدى الأطفال في الإمارات بمشاركة 200 طبيب وصيدلي", which translates as "Opella launches Telfast Kids for allergy in children in the UAE with the participation of 200 doctors and pharmacists". The link resolves to the full Dawaa News MENA article, dated 3 November 2026 and filed from Dubai.
For BioNixus, Dawaa News is an alert layer. We treat it as the trigger for research, not as the only source for the wider picture. In this case, though, the launch event itself has not yet appeared in an Opella press release or a regulator notice that we could find, so the event specifics below rest on the Dawaa News report and the executive post it cites.
What was announced
The Dawaa News report makes five points that can be stated with confidence:
- Opella announced the launch of Telfast Kids in the UAE, extending the Telfast brand into children's allergy care.
- The launch took place during scientific events that ran over two days.
- About 200 doctors and pharmacists took part.
- The launch was held in collaboration with the Emirates Pediatric & Neonatal Society (EPNS).
- Hossam Abo Ouf, who heads Opella in Saudi Arabia and the UAE, disclosed the launch on LinkedIn and thanked EPNS, the speakers, the participating healthcare professionals and the Opella UAE team.
Just as useful is what the report says was not disclosed. Dawaa News notes that the announcement did not name all speakers or session topics, did not state the number of participating healthcare institutions, and did not give the strength, dosage form, approved age groups, price or sales targets for the product launched in the UAE. The report also stresses that indications, dosing and age groups remain governed by the product leaflet and the regulatory information approved in the UAE.
That discipline matters for anyone writing about the launch, including us. We do not know the UAE pack format of Telfast Kids from public sources, so this article does not assume one.
Who is Opella, and why the Telfast name matters
Opella is no longer part of Sanofi's operating structure. On 30 April 2025, Sanofi announced the closing of the sale of a 50.0% controlling stake in Opella to the investment firm CD&R. Sanofi kept a 48.2% stake and Bpifrance took 1.8%. Sanofi said it received total net cash proceeds of around EUR 10 billion.
At the time of closing, Sanofi described Opella as headquartered in France, employing more than 11,000 people, operating in 100 countries with 13 manufacturing sites and four science and innovation development centres, and serving more than half a billion consumers. Sanofi also described it as the third-largest business worldwide in the OTC and vitamins, minerals and supplements (VMS) market.
Telfast is one of Opella's flagship names. The Opella boilerplate in its 1 July 2026 Zawya release lists Telfast first among "the world's most loved brands" it makes, alongside Dulcolax, Enterogermina, Pharmaton and Buscopan. In the United States the same molecule, fexofenadine, is sold under the Allegra name, which the Sanofi closing release lists among Opella's iconic brands. In the Middle East, including Egypt where Opella runs a local Telfast website, the brand is sold as Telfast.
A brand extension into children's allergy is a classic consumer health move. It takes a name that adults and prescribers already know and moves it into a new need state where parents want reassurance. The commercial question is whether trust in the adult brand transfers to a paediatric purchase. That is a research question as much as a marketing one.
Opella's recent Gulf activity
The UAE launch did not happen in isolation. In its 1 July 2026 release marking a year of independence, Opella said that in Saudi Arabia it had launched five new products in the previous 12 months across allergy, cough and digestive wellness, and that its products were available through more than 4,600 pharmacies in the Kingdom as well as authorised e-commerce pharmacy platforms. The same release described pharmacists as "among the most trusted and accessible sources of health advice for consumers".
A day before the UAE story, on 2 November 2026, Dawaa News reported a separate Opella programme in Saudi Arabia that aims to train about 800 pharmacists on allergy and air pollution in its first phase and to reach about 20,000 people with awareness messages during the fourth quarter of 2026. Dawaa News was careful to describe those numbers as announced targets, not results. We repeat them with the same caveat.
Read together, the pattern is clear. Opella's Gulf playbook in allergy leans heavily on the pharmacist and on scientific engagement with healthcare professionals (HCPs).
The epidemiology: why paediatric allergy is a real category in the UAE
Launch events need a reason to exist. In the UAE, the burden of allergic symptoms in children is well documented in peer-reviewed literature, mostly using the International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire.
The 2021 Dubai and Northern Emirates study
The most recent large study we found was published in the World Allergy Organization Journal in October 2021 by Ibrahim and colleagues. It recruited children through school class registers in Dubai and the Northern Emirates between March and June 2019, using the Arabic and English ISAAC core questionnaires. The analysis included 3,436 children in two age groups, 6 to 7 years and 13 to 14 years.
The key findings for allergic rhinitis symptoms were striking:
- Any history of sneezing or a runny or blocked nose not related to a cold or flu: 46.5% in 6 to 7 year olds and 51.3% in 13 to 14 year olds.
- The same symptoms in the past 12 months: 42.6% and 45.9% respectively.
- Any history of hay fever: 22.1% and 19.9%.
- Moderate to severe nose problems that interfered with daily activity: 36.8% of children aged 6 to 7 and 20.4% of those aged 13 to 14.
The same study reported asthma prevalence of 11.9% in the younger group and 9.8% in the older group, and atopic dermatitis of 12.9% and 14.6%. The authors concluded that allergic disorders are a healthcare burden in the UAE and called for nationwide efforts to detect undiagnosed children.
Earlier UAE data points
Older studies support the same direction. A 2000 study by al-Maskari and colleagues, which used ISAAC questionnaires with about 3,200 government primary school children aged 6 to 13 across seven emirates, reported hay fever prevalence of 14.9% and physician-diagnosed asthma of 13%. A separate study published in the Journal of Allergy and Clinical Immunology, set in a Bedouin Arab population in the UAE, found self-reported allergic rhinitis in the past 12 months of 39.7% among children.
These studies use different populations, age bands and definitions, so the numbers should not be stacked or averaged. The honest summary is that symptom-based allergic rhinitis is common in UAE children by any of these measures, and that the burden is large enough to justify sustained clinical and commercial attention.
What the data does not tell you
Symptom prevalence is not the same as diagnosed disease, and neither is the same as treated patients. None of the studies above tells a brand team how many UAE parents buy an antihistamine for a child each year, how often they ask a pharmacist first, or how often a paediatrician's advice decides the brand. Those are the numbers that drive a forecast, and they are not in the public domain. They have to be measured.
The regulatory frame has changed under the launch
Any 2026 UAE launch sits inside a regulatory system that has been reorganised in the last two years. Federal Decree-Law No. 38 of 2024 governs medical products, pharmacists and pharmaceutical establishments and set up the Emirates Drug Establishment (EDE) as the federal medicines authority.
On 31 December 2025, WAM reported that MoHAP had transferred 44 core services fully to the EDE, covering areas such as re-pricing of medical products, manufacturer registration, price list publication and pharmacovigilance approvals. A further 13 services were shared between the two bodies, including the issuance and renewal of health advertising licences and appeals against health advertising violations. Five narcotics-related services stayed with MoHAP.
MoHAP's own Arabic service page lists marketing approvals for medical products, approval of advertising and promotion for medical products, and registration of general sale pharmaceutical products among the services moved to the EDE. It also notes that community and compounding pharmacies remain within MoHAP's scope.
For consumer health teams, two practical points follow:
- Promotion rules and approvals now run through a changed set of counters. Any consumer-facing Telfast Kids campaign, or any competitor response, will need advertising approval under the current split of EDE and MoHAP responsibilities. Teams should map which body signs off which material before they plan a consumer burst.
- Pharmacy-level behaviour is still shaped by a different regulator than product approval. Product authorisation and the community pharmacy are overseen by different bodies. That is one more reason the pharmacist counter deserves its own research stream.
BioNixus covered the pricing side of this shift in our earlier analysis of UAE drug pricing, the EDE takeover and launch research.
Why the launch format matters: three channels, three jobs
The most instructive detail in the Dawaa News report is the audience. Opella chose about 200 doctors and pharmacists, convened with a paediatric society, over two days. That points to three distinct channels in the UAE paediatric allergy market, each with its own job.
1. The paediatrician sets the reference point
Paediatricians and family physicians define what "safe for my child" looks like for many parents. A paediatric society partnership gives a brand a scientific setting to discuss the molecule, dosing by age and safety considerations, within the limits of the locally approved label. Even when the product is bought over the counter, a doctor's past advice often shapes which box a parent asks for.
For a brand team, the questions are concrete. Which UAE paediatricians already recommend fexofenadine, and for which ages? What do they see as the main alternatives? How do they talk about sedation, school performance and dosing convenience? And how does that differ between private clinics in Dubai and public facilities in Abu Dhabi and the Northern Emirates?
2. The pharmacist converts the moment of need
Children's allergy often presents as a sudden need: a runny nose that is not a cold, itchy eyes in a dusty week, a parent standing at the counter. In that moment the pharmacist is the decision point. Opella's own Saudi messaging calls pharmacists among the most trusted sources of health advice, and its separate Saudi training programme targets 800 of them.
The research questions here are about behaviour, not attitude. What do UAE pharmacists actually recommend when a parent asks for a children's allergy product? Do they ask about age and symptoms first? Do they switch a parent away from the requested brand? Does a launch event change what they say at the counter three months later? Mystery shopping and pharmacist panels can answer these questions. Launch attendance numbers cannot.
3. The parent pays, and often decides
Parents are the end consumer, the payer and frequently the final decision maker. Their choices respond to brand familiarity, price, taste and format, pack information in Arabic and English, and digital content. In the UAE, where the population is highly diverse in nationality and language, parent research needs to be designed so that it does not mistake one community's habits for the market's.
What the 200-HCP number does and does not mean
Two hundred doctors and pharmacists in two days is a meaningful engagement for a single launch in one country. It shows commitment and gives the brand a base of informed advocates.
But as Dawaa News itself pointed out, the number of attendees is not a measure of clinical results, expected market share or future commercial performance. It is an input. The outputs that matter are later: recall of key messages, intention to recommend, actual recommendation behaviour, and parent purchase. A launch team should plan to measure the distance between the input and those outputs from the first week.
Launch evidence needs for paediatric OTC in the UAE and GCC
Based on the structure of this launch, here is the evidence a consumer health team would typically need before and after a similar paediatric allergy launch in the region.
Before launch
- Category sizing from the bottom up. Combine published symptom prevalence with primary data on treatment-seeking behaviour, so the forecast reflects how many children are actually treated, not just how many have symptoms.
- Channel role mapping. Quantify how often the purchase starts with a doctor's advice, a pharmacist's recommendation, a parent's own brand choice or an online search.
- Message and concept testing with HCPs. Test which claims, within the approved label, are credible to paediatricians and pharmacists, and which raise questions.
- Parent concept and pack testing. Test format, flavour, dosing device and bilingual pack information with parents from the main nationality groups.
- Regulatory and promotional readiness. Map the approval path for advertising under the EDE and MoHAP split, so that research findings can turn into approved materials quickly.
At launch
- Event effectiveness research. Short follow-up surveys with attending doctors and pharmacists measure message take-out and intent to recommend, compared with a matched group that did not attend.
- Early pharmacy audits and mystery shopping. Check availability, shelf visibility and what pharmacists say when a parent asks for a children's allergy product.
After launch (3 to 12 months)
- Recommendation tracking. Repeat pharmacist and paediatrician waves to see whether recommendation shares move and stay moved.
- Parent usage and satisfaction. Measure repeat purchase intent, perceived effectiveness, ease of dosing and any concerns that reach the pharmacist or doctor.
- Competitive response monitoring. Track competitor promotions, pricing moves and pharmacist incentives.
- GCC read-across. Compare UAE results with Saudi Arabia and other GCC markets where the same brand is active, to see which parts of the playbook travel.
What this means for teams across the GCC
Three lessons stand out for consumer health, OTC and pharma teams in the region.
First, paediatric OTC launches in the Gulf are being run like scientific launches. A paediatric society partnership and a doctor and pharmacist audience look more like a prescription-medicine launch than a mass-market consumer launch. Teams that rely only on retail promotion may find the professional channel already occupied.
Second, the pharmacist is a deliberate investment target. Opella's Saudi training programme and the pharmacist-heavy UAE launch audience suggest that consumer health companies see pharmacist recommendation as a lever worth building. Competitors should measure their own pharmacist recommendation share now, while there is still a baseline to compare against.
Third, evidence gaps are the norm, not the exception. The public record on this launch does not include pack format, price, age range or targets. That is normal for an OTC launch. It means teams cannot benchmark competitors from press coverage alone. They need primary data from the counter, the clinic and the home.
How BioNixus helps
BioNixus has run healthcare and B2B market research since 2012, with 118 clients in 48 countries. Our physician network is 82,000+ physicians globally and about 3,200 in the Middle East. We work from our Americas office and global HQ in the USA, our Europe office in the UK, our AMEA office in Cairo and our UAE field office in Dubai.
For a paediatric allergy or wider OTC antihistamine launch in the UAE and GCC, we can support:
- Paediatrician and family physician surveys and interviews on recommendation patterns, perceived alternatives and message credibility.
- Pharmacist research, including quantitative panels, in-depth interviews and pharmacy mystery shopping to measure what is actually said at the counter.
- Parent and caregiver research in Arabic and English, designed for the UAE's mixed nationality population.
- Launch event effectiveness and recommendation tracking to connect HCP engagement to behaviour over time.
- GCC comparisons across the UAE, Saudi Arabia, Kuwait, Qatar, Bahrain and Oman.
You can read more about our UAE consumer health market research work and our view of the GCC OTC drugs market.
Plan your UAE paediatric allergy and OTC research with BioNixus
If you are planning a paediatric OTC launch in the UAE or GCC, or responding to one, start with evidence from the people who decide: paediatricians, pharmacists and parents. Visit bionixus.com or contact our team to scope a study.
This article summarises public announcements, regulatory notices and published epidemiology. It is not medical, legal or regulatory advice, and it does not recommend any medicine. Product use in the UAE is governed by the locally approved product information.
